Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BraimTOR-ONKO rapamycin in pediatric high-grade glioma
2021-006689-18Phase 2Active
- Sponsor
- Children's Memorial Health Institute
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sirolimus in glioma (2 arms), sponsored by Children's Memorial Health Institute. Primary endpoint: Incidence of grade 3 and 4 adverse reactions. Started Oct 2022; status: active.
02
Drugs
sirolimus
03
Conditions
glioma
Beyond the preview
Go deeper on 2021-006689-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006689-18.